UNLIMITED TURBO BULL - NOVO-NORDISK B | Real-time Euronext Paris 09:48:29 23/05/2024 BST | ||
| 7.54 EUR | +2.86% |
|
| Current month | +5.47% | ||
| 1 month | +8.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 7.54 | +2.86% |
| 22/05/24 | 7.33 | -0.27% |
| 21/05/24 | 7.35 | +2.51% |
| 20/05/24 | 7.17 | +1.41% |
| 17/05/24 | 7.07 | -2.08% |
Real-time Euronext Paris
Last update May 23, 2024 at 09:48 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| 4K17S | |
| ISIN | DE000SQ4ZV03 |
| Date issued | 30/11/2022 |
| Strike | 377.7 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.27 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.75 € |
|---|---|
| Lowest since issue | 1.23 € |
| Spread | 0.01 € |
| Spread % | 0.13% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- 4K17S Certificat
